Compare Novo Nordisk A/S (NVO) vs Invesco S&P 500 Low Volatility ETF (SPLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Invesco S&P 500 Low Volatility ETF — how do they compare? Novo Nordisk A/S trades at $38.44 (market cap $165.31B), while Invesco S&P 500 Low Volatility ETF trades at $72 (market cap $6.94B). The key difference: Novo Nordisk A/S is far larger — about 23.8× Invesco S&P 500 Low Volatility ETF's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Invesco S&P 500 Low Volatility ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Invesco S&P 500 Low Volatility ETF for 123 Days on average.
| NVO | SPLV | |
|---|---|---|
Market Cap | $165.31B | $6.94B |
Volume | 11,432,838 | 1,663,703 |
Sector | Health | — |
52-Week High | $63.98 | $77.97 |
52-Week Low | $35.29 | $70.30 |
Typical Hold Time | 116 Days | 123 Days |
Enterprise Value | $179.56B | — |
Dividend Yield | 4.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.26, up 1.95% today, with a bullish technical signal supported by oscillators like RSI at 20.06 (buy signal). The company shows strong fundamentals with a P/E of 9.66, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights pipeline developments, including a Wegovy pill study showing continued weight loss and a $4 billion licensing deal, though an FDA delay for a hemophilia drug poses a near-term headwind.
The outlook remains positive with a consensus price target of $44.67, implying 17% upside, driven by robust profitability and growth in GLP-1 therapies. Risks include competitive pressure from Eli Lilly, regulatory delays, and reliance on obesity/diabetes drugs. Analyst sentiment is bullish (59% buy ratings), but investors should monitor execution amid high expectations.
SPLV trades at $71.99, up 1.08% with a bearish technical outlook from moving averages. The ETF's sector overweights in Utilities, Real Estate, and Financials have contributed to underperformance versus the S&P 500. Recent dividend payments of $0.14 provide income support, while technical indicators show mixed signals with neutral oscillators.
Outlook remains cautious due to sector headwinds and unappealing growth-adjusted valuation. The fund's low-volatility focus offers defensive positioning amid market uncertainty, though continued underperformance relative to broader market indexes presents near-term challenges for total return investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Invesco S&P 500 Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the "index Provider") compiles, maintains and calculates the underlying index, which is designed to measure the performance of the 100 least volatile constituents of the S&P 500 ® Index over the past 12 months as determined by the index Provider.
Read more on SPLV →
